R788 (fostamatinib disodium): A novel approach for the treatment of rheumatoid arthritis

International Journal of Clinical Rheumatology

Volumn 5, Issue 1, 2010, Pages 9-15

  Morales Torres, Jorge ^a  

^a Hospital Aranda de la Parra   (Mexico)

Author keywords

Fostamatinib disodium; Kinase inhibitors; R788; Rheumatoid arthritis; Syk kinase

Indexed keywords

ANTIRHEUMATIC AGENT; DISEASE MODIFYING ANTIRHEUMATIC DRUG; FOSTAMATINIB DISODIUM; HYDROXYCHLOROQUINE; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; PREDNISONE; PROTEIN KINASE SYK; R 406; R 788; SALAZOSULFAPYRIDINE; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANOREXIA; AREA UNDER THE CURVE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BLADDER CANCER; CHICKENPOX; CHOLECYSTITIS; CLINICAL TRIAL; COUGHING; DEHYDRATION; DIARRHEA; DIZZINESS; DOSE RESPONSE; DRUG COMPETITION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG ERUPTION; DRUG EXCRETION; DRUG EXPOSURE; DRUG FEVER; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG METABOLISM; DRUG POTENCY; DRUG SAFETY; DRUG WITHDRAWAL; DYSLIPIDEMIA; ENZYME ACTIVATION; ENZYME INHIBITION; FOOD; FOOD DRUG INTERACTION; GASTRITIS; GASTROINTESTINAL DISEASE; GASTROINTESTINAL TOXICITY; HUMAN; HYPERTENSION; HYPOTHYROIDISM; INFLUENZA; MAXIMUM PLASMA CONCENTRATION; NAUSEA; NEUTROPENIA; NONHUMAN; PHARMACODYNAMICS; PHARYNGITIS; PNEUMONIA; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS; SIDE EFFECT; SINGLE DRUG DOSE; TIME TO MAXIMUM PLASMA CONCENTRATION; UNSPECIFIED SIDE EFFECT; UPPER ABDOMINAL PAIN; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; VAGINA BLEEDING; VOMITING;

EID: 77950205371     PISSN: 17584272     EISSN: None     Source Type: Journal    
DOI: 10.2217/ijr.09.69     Document Type: Review

References (23)

1. MacGregor AJ, SilmanAJ: Classification and epidemiology. In: Rheumatology (4th Edition). Hochberg MC, Silman AJ, Smolen JS, Weinblatt ME, Weisman MH (Eds). Mosby Elsevier, PA, USA 755-761 (2008).
2. Gravallese EM, Monach PA: The rheumatoid joint: synovitis and tissue destruction. In: Rheumatology (4th Edition). Hochberg MC, Silman AJ, Smolen JS, Weinblatt ME, Weisman MH (Eds). Mosby Elsevier, PA, USA 841-865 (2008).
3. Tetlow LC, Woolley DE: Mast cells, cytokines, and metalloproteinases at the rheumatoid lesion: dual immunolocalisation studies. Ann. Rheum. Dis. 54, 896-903 (1995).
4. Wooley DE, Tetlow LC: Mast cell activation and its relation to proinflammatory cytokine production in the rheumatoid lesion. Arthritis Res. 2, 65-74 (2000).
5. Abrahams VM, Cambridge G, Lydyard PM, Edwards JC: Induction of tumor necrosis factor a production by adhered human monocytes: a key role for Fc g receptor type IIIa in rheumatoid arthritis. Arthritis Rheum. 43, 608-616 (2000).
6. Wolfe F, Sharp JT: Radiographic outcome of recent-onset rheumatoid arthritis: a 19 year study of radiographic progression. Arthritis Rheum. 41, 1571-1582 (1998).
7. Giles JT, Bathon JM: Management of rheumatoid arthritis: synovitis. In: Rheumatology (4th Edition). Hochberg MC, Silman AJ, Smolen JS, Weinblatt ME, Weisman MH (Eds). Mosby Elsevier, PA, USA 887-895 (2008).
8. Savage C, St Clair EW: New therapeutics in rheumatoid arthritis. Rheum. Dis. Clin. North Am. 52, 57-74 (2006).
9. Schett G, Zwerina J, Firestein G: The p38 mitogen-activated protein kinase (MAPK) pathway in rheumatoid arthritis. Ann. Rheum. Dis. 67, 909-916 (2008).
10. Karcher SC, Laufer SA: Successful structure-based design of recent p38 MAP kinase inhibitors. Curr. Top. Med. Chem. 9, 655-676 (2009).
11. Cohen SB, Cheng TT, Chindalore V et al.: Evaluation of the efficacy and safety of pamapimod, a p38 MAP kinase inhibitor, in a double-blind, methotrexate-controlled study of patients with active rheumatoid arthritis. Arthritis Rheum. 60, 335-344 (2009).
12. Damjanov N, Kauffman RS, Spencer-Green GT: Efficacy, pharmacodynamics, and safety of VX-702, a novel p38 MAPK inhibitor, in rheumatoid arthritis: results of two randomized, double-blind, placebo-controlled clinical studies. Arthritis Rheum. 60, 1232-1241 (2009).
13. Wong BR, Grossbard EB, Payan DG, Masuda ES: Targeting Syk as a treatment for allergic and autoimmune disorders. Expert Opin. Investig. Drugs 13, 743-762 (2004).
14. Cha HS, Boyle DL, Inoue T et al.: A novel spleen tyrosine kinase inhibitor blocks c-Jun N-terminal kinase-mediated gene expression in synoviocytes. J. Pharmacol. Exp. Ther. 317, 571-578 (2006).
15. Braselmann S, Taylor V, Zhao H et al.: R406, an orally available spleen tyrosine kinase inhibitor blocks fc receptor signaling and reduces immune complex-mediated inflammation. J. Pharmacol. Exp. Ther. 319, 998-1008 (2006).
16. Pine PR, Chang B, Schoettler N et al.: Inflammation and bone erosion are suppressed in models of rheumatoid arthritis following treatment with a novel Syk inhibitor. Clin. Immunol. 124, 244-257 (2007).
17. Grossbard E, Baloum M, Kivitz AJ: a Phase I randomized, double-blind, placebo controlled pharmacokinetic study of R788/406 and methotrexate in sixteen patients with rheumatoid arthritis. Abstract Supplement, 2006 Annual Scientific Meeting, Washington DC, USA. Arthritis Rheum. 54(Suppl.), S408 (2006).
18. Weinblatt ME, Kavanaugh A, Burgos-Vargas R et al.: Treatment of rheumatoid arthritis with a Syk kinase inhibitor: a 12 week, randomized, placebo-controlled trial. Arthritis Rheum. 58, 3309-3318 (2008).
19. Weinblatt ME, Kavanaugh A, Genovese M, Grossbard E, Magilavy D: Treatment of rheumatoid arthritis (RA) with an oral Syk kinase inhibitor: a 6 month randomized placebo controlled Phase 2b study in patients with active RA on chronic methotrexate. Abstract Supplement, 2009 Annual Scientific Meeting, Philadelphia PA, USA, Arthritis Rheum. 60(Suppl.), LB-2 (2009).
20. Genovese M, Kavanaugh A, Peterfy C, Magilavy D: An oral Syk kinase inhibitor in the treatment of rheumatoid arthritis(RA): a 3 month randomized placebo controlled Phase 2 study in patients with active RA who had failed biologic agents. Abstract Supplement, 2009 Annual Scientific Meeting, Philadelphia PA, USA, Arthritis Rheum. 60(Suppl.), LB-3 (2009).
21. Psaila B, Bussel JB: Fc receptors in immune thrombocytopenias: a target for immunomodulation? J. Clin. Invest. 118, 2677-2681 (2008).
22. Podolanczuk A, Lazarus AH, Crow AR, Grossbard E, Bussel JB: Of mice and men: an open-label pilot study for treatment of immune thrombocytopenic purpura by an inhibitor of Syk. Blood 113, 3154-3160 (2009).
23. Bahjat FR, Pine PR, Reitsma A et al.: An orally bioavailable spleen tyrosine kinase inhibitor delays disease progression and prolongs survival in murine lupus. Arthritis Rheum. 58, 1433-1444 (2008).